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Background: T-cell infiltration in primary colon tumors is associated with improved patient survival. Preliminary
data supports a similar association in colorectal liver metastases (CRLM), and we previously identified increased
CRLM expression of the immunostimulatory cytokine LIGHT (TNFSF14) to be related to improved patient prognosis.
Therefore, mechanisms to augment the T-cell response in CRLM may be a promising treatment modality, however,
the tumor immune microenvironment and LIGHT expression in CRLM remains to be characterized.
Methods: Utilizing a syngeneic and immunocompetent model of CRLM, the immune microenvironment was
characterized for lymphocyte phenotype, function, and location utilizing flow cytometry, immunoassays, and
immunofluorescence microscopy.
Results: CD3+ and CD4+ lymphocytes were decreased, and CD8+ cells were increased in CRLM compared to
control liver. When present, greater populations of tumor infiltrating lymphocytes (TIL) were found peritumoral than
intratumoral. The TIL expressed significantly higher levels of CD69 and CD107a, but lower levels of LIGHT. Cytokine
expression profiles revealed increased levels of the T-helper 1 (Th1) cytokines IFN gamma, IL-12, IL-1b, and IL-8 in
CRLM compared to control liver tissue. There was no difference in T-helper 2 (Th2) cytokines between the groups.
Conclusions: Characterization of the tumor microenvironment of CRLM revealed that although a limited number of
activated T-cells infiltrate the tumor and initiate an immune response, the number of LIGHT + T cells infiltrating the
tumor were very low. Techniques to decrease suppressive influences or augment the cytotoxic T-cell response are
needed and may be possible through mechanisms that can increase intratumoral TIL LIGHT expression.
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Almost 5% of the global population [1] is diagnosed with
colon cancer and roughly 608,000 people die from colo-
rectal cancer annually [2]. These numbers are increasing
as colorectal cancer incidence rises, possibly secondary
to changes in lifestyle patterns [3]. Within the United
States, colorectal cancer is expected to be responsible for
over 140,000 new cancer cases among men and women,
accounting for 8% of cancer deaths in men and 9% of* Correspondence: amaker@uic.edu
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reproduction in any medium, provided the orcancer deaths in women [4]. Even though colorectal can-
cer mortality decreased in the United States between
1976-2000, most of this improvement was secondary to
improved screening (53%) while improvements in treat-
ment only decreased mortality by 12% [1]. Therefore, in
addition to raising awareness of risk factors and continu-
ing to improve surveillance, there is a need to also im-
prove colorectal cancer therapies.
The majority of patients with advanced colorectal can-
cer will die of metastatic disease, most commonly to the
liver. Colorectal cancer liver metastases (CRLM) develop
in 20% of patients with Stage II colon cancer, and 50% of
patients with stage III colon cancer [5]. In highly se-
lected cases, surgical resection may provide long-term
survival, however, only 10-20% of patients are candidates. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gery, only 40% reach 5-year survival [5].
Standard management of diffuse CRLM involves
multidrug chemotherapy regimens [6]. In addition to
treatment-related toxicity, the chemotherapeutic regi-
mens are limited in that they are often tumoristatic.
The development of novel tumoricidal cancer therapies
is needed.
The presence of T-cell infiltrates in primary colon tu-
mors is more prognostic than traditional TNM staging
and more directly correlates with overall survival [7].
Furthermore, we and others have shown that increased
CD4 and CD8 T-cell infiltrates, and decreased Foxp3+ T
regulatory cell ratios, in CRLM are also associated with
improved overall survival [8,9]. We have also demon-
strated in preliminary gene array studies that T cell
proliferation is the most significant biological process
associated with survival in patients with colorectal can-
cer liver metastases [10]. Therefore, mechanisms to
improve the immunogenicity of CRLM or augment the
T-cell response may be a promising treatment modality
for these patients.
LIGHT (TNFSF14) is an immunostimulatory cytokine
that has been shown to augment the anti-tumor immune
response and whose overexpression we identified as be-
ing associated with improved overall and recurrence free
survival in patients with CRLM [10]. A member of the
Tumor Necrosis Factor Superfamily (TNFSF), it bears
close homology with lymphotoxin a-β, lymphotoxin α,
and Fas ligand. LIGHT is expressed predominantly on
lymphocytes, and it principally interacts with two recep-
tors – Lymphotoxin β receptor, located on other lym-
phocytes, and herpesvirus-entry-mediator (HVEM),
which is located mainly on stromal cells [11]. Forced
LIGHT overexpression in tumors leads to increased
levels of cytotoxic T lymphocytes (CTLs) in and around
the tumor and can induce tumor regression [12]. LIGHT
may allow CTL’s to overcome the antigenic barrier
formed by host cell stroma around the tumor and to
mount an anti-tumor response [13]. In order to deter-
mine the utility of LIGHT and other immunostimulatory
cytokines for CRLM immunotherapy, the tumor micro-
environment of CRLM first requires characterization,
which has not yet been performed. The purpose of our
research is to accurately determine the intra and peri-
tumoral immunologic milieu of CRLM and the expres-
sion and location of LIGHT within it.
Methods
Cell Culture, Cell Staining, and FACS analysis
CT26 murine colorectal carcinoma cell line was obtained
from the American Type Culture Collection (ATCC,
Manassas, VA, USA) and was grown in RPMI 1640
culture medium (Sigma-Aldrich, St. Louis, MO, USA)supplemented with 10% fetal bovine serum (Invitrogen,
Grand Island, NY, USA) and 1% Anti-Anti (Invitrogen,
Grand Island, NY, USA). Antibodies for staining leuko-
cytes and FACS analysis included anti-mouse CD3, CD4,
CD8, CD25, CD107a, CD69, and Foxp3 (eBioscience
Inc., San Diego, CA, USA). Anti-mouse-Light-A647 was
internally validated (eBioscience Inc., San Diego, CA,
USA). Gating references for lymphocytes were established
by forward and side scatter profiles of corresponding per-
ipheral blood mononuclear cells.
Intrahepatic lymphocytes and tumor infiltrating lym-
phocytes were treated with PMA and Ionomycin and
stained for cell surface makers. After fixation with
Cytofix/Cytoperm buffer (Becton Dickinson) cells were
stained with anti-Light antibody (eBioscience Inc., San
Diego, CA, USA). Stained cells were analyzed on a CyAn
ADP analyzer (Beckman Coulter, Brea, CA, USA). Events
were collected and analyzed using Flow Jo software (Tree
Star Incorporated, Ashland, OR, USA).
Lentivirus production and infection
A bicistronic lentiviral vector (pHIV1SDm-CMV-GFP-
P2A-luc) simultaneously expressing GFP and firefly lu-
ciferase was utilized. 293FT cells were transfected with
the lentiviral vector and pcDNA3-Tat, pHCMV-Rev,
pHCMVgagpol, and pHCMV-G (kindly provided by
Dr. Jeff Holst, University of Sydney, Sydney, Australia).
Using a calcium precipitation method [14], a stably
transduced CT26 cell line that expressed both GFP and
luciferase was created.
Mouse model of colorectal cancer liver metastases
Female BALB/c mice weighing 18–20 g were purchased
from Charles River Laboratories (Wilmington, MA,
USA) and maintained in specific pathogen-free condi-
tions. All animal care and surgical procedures were
performed in accordance with protocols approved by the
Office of Animal Care and Institutional Biosafety
(OACIB) of University of Illinois at Chicago (Chicago,
Illinois, USA). Mice were anesthetized and a laparotomy
was performed. 1x106 CT26 cells in 0.1ml of PBS or PBS
alone (for control group) was injected into the spleen
parenchyma followed by splenectomy in both groups.
Tumor growth was monitored by bioluminescence im-
aging of live animals with the Xenogen in vitro imaging
system (Caliper Life Sciences, Inc., Hopkinton, MA).
Isolation of intrahepatic lymphocytes and tumor
infiltrating lymphocytes
Mice were euthanized by CO2 inhalation. Livers were im-
mediately perfused through the portal vein with 5 mL of
PBS and livers were then surgically resected. The meta-
static liver tumors (CRLM) were surgically macrodissected
at the border between obvious tumor tissue and healthy
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RPMI containing 5% FBS, collagenase IV (1 mg/ml,
Sigma), and DNase I (50 ug/ml, Sigma); and strained
to obtain a single cell suspension. A mononuclear
cell-enriched fraction was isolated using Percoll centri-
fugation media (GE Healthcare Biosciences, Pittsburgh,
PA, USA), and cell viability determined by trypan blue
exclusion, which was >90%.
Peripheral blood mononuclear cell (PMBC) isolation
Following euthanasia, mouse peripheral blood was
obtained via retroorbital bleed. Blood specimens from
3-4 mice were pooled and loaded onto the top of a
Ficoll-Hypaque centrifugation column per manufac-
turer’s instructions. The lymphocyte-enriched layer was
collected and red blood cells were lysed with ACK lys-
ing buffer (Invitrogen, Grand Island, NY, USA).
Protein extraction from control liver or liver metastases
Fresh surgically dissected control liver or CRLM were
immediately frozen in liquid nitrogen and stored in -
70°C for protein preparation. Frozen specimens were
pulverized (Biopulverizer, BioSpec Products, Bartles-
ville, OK, USA) and lysed with 1% Triton-X100, 0.5%
NP-40, 0.25% Na-deoxycholate, 1 mM EDTA, 1 mM
EGTA, 5 mM NaF, 1 mM orthovanadate, 1 uM
microcytin, 1 mM AEBSF and complete protease in-
hibitor cocktail per manufacturer’s instructions (Roche,
Indianapolis, IN, USA). Protein concentrations were
measured using Bradford reagents (Bio-Rad Laboratories,
Hercules, CA, USA).
Cytokine assay
Cytokine quantification in control liver and CRLM was
performed with a mouse Th1/Th2 ultrasensitive im-
munoassay (Meso Scale Discovery, Gaithersburg, MD,
USA) following the manufacturer’s protocol. The kit was
used to detect mouse IFN-gamma, IL-1 beta, IL-2, IL-4,
IL-5, IL-8, IL-10, and total IL-12 in a sandwich immuno-
assay format. The plate was read on the SECTOR imager
and analyzed with MSD Discovery Workbench Software
(Meso Scale Discovery, Gaithersburg, MD, USA).
Immunofluorescence
Surgically resected control liver and tumors were em-
bedded in OCT (Tissue-Tek, Sakura Finetek, Torrance,
CA, USA). For concurrent staining of LIGHT, CD3,
CD4, and CD8, 6μm cryostat sections were prepared.
Slides were fixed in acetone, blocked in 5% BSA, and in-
cubated with LIGHT affinity-purified goat anti-LIGHT
antibody (AF1794, R&D Systems, Minneapolis, MN,
USA) followed by affinity purified donkey anti-goat IgG
conjugated to FITC (sc-2024 Santa Cruz Biotechnology,
Santa Cruz, CA). T-cell markers were stained with Anti-Mouse CD3, CD4, or CD8 conjugated to AlexaFluorW
700 (eBioscience, San Diego, CA, USA). Following sec-
ondary antibody incubation, sections were washed and
mounted using UltraCruz Mounting Medium containing
DAPI (sc-24941, Santa Cruz Biotechnology, Santa Cruz,
CA, USA). Ag104 cells that stably overexpressed LIGHT
[15] were used as a positive control (gift of Dr. Yang Xin
Fu). Ag104 cell monolayers were grown in Lab-Tek
Chamber Slides (Nalge Nunc International, Rochester,
NY, USA) to 70-80% confluence and then washed, fixed
and appropriately stained. As a negative control, CT26
colon carcinoma cells were grown in culture and han-
dled using the same protocol. They were confirmed to
show no LIGHT signal via immunofluorescence and
verified to express no LIGHT via western blot and FACS
analysis (data not shown). Immunofluorescence and
photographs were obtained with an Olympus BX51
fluorescence microscope in the RRC Confocal Micros-
copy Facility (University of Illinois Chicago, Chicago,
Illinois, USA). Images were acquired using an Olympus
DP71 CCD camera and DP Controller Software (Olympus,
Center Valley, PA, USA).
TIL quantification was performed according to our
standard clinical pathology protocol for primary colon
cancers and CRLM, as has previously been reported and
is utilized by many groups [16-18]. In brief, only cells in-
filtrating between tumor cells were counted and apop-
totic cells were not included. The tumor was reviewed at
low power and an area with the most TIL or lympho-
cytes was identified. In this location, five consecutive
400× fields were counted and the mean TIL/high power
field for each tumor was then calculated. Peritumoral
lymphocytes were considered the lymphoid cuff at the
leading edge of the tumor [16].
Statistical analysis
Data were presented along with the standard error of
the mean (SEM) where appropriate. Differences between
groups were calculated using the student two–tailed
t-test (Microsoft Excel, Redmond, Washington: Microsoft,
2007). Significance was considered for p-values < 0.05.
Results
Phenotype and function of T cell subsets in colorectal
liver metastases
Mice were sacrificed two weeks post operation after
tumor burden and isolated colorectal liver metastases
were confirmed by bioluminescence imaging (Figure 1).
The number of CD3+ cells as a percentage of total lym-
phocytes in metastatic tumor tissue was lower com-
pared to the number of CD3+ T cells in corresponding
control liver (mean ± SEM : 37.5% ± 1.4 vs. 51.6 % ± 1.5,
p = 0.00001). Similarly, CD4+ tumor infiltrating lympho-
cytes (TIL) as a percentage of total lymphocytes were
A B
Isolated colorectal liver 
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Figure 1 Control mice underwent saline injection followed by splenectomy (A). Isolated colorectal liver metastases formed in immunocompetent
mice after intrasplenic injection of a syngeneic colorectal carcinoma line (B). Isolated colorectal liver metastases were confirmed by bioluminescence
imaging prior to sacrifice (C).
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(8.7% ± 1.9 vs. 18.8% ± 2.5, p = 0.00002)(Figure 2A).
There was no difference in total CD8+ cell populations
between the tumor and control groups (11.7% ± 0.5 vs.
15.2% ± 1.3, p = 0.17). When CD4+ and CD8+ cell pop-
ulations were determined as a percentage of CD3+
cells, CD3 + CD4+ populations again trended to be less
in tumor deposits than normal liver (22.4% ± 5.6 vs.
34.5% ± 5.4, p = 0.14), but CD3 + CD8+ cells were sig-
nificantly increased (38.6% ± 3.2 vs. 20.2% ± 1.7, p =
0.00006) (Figure 2B). There was no difference in CD4 +
CD25 + Foxp3+ T regulatory cell populations between
the groups, and their expression was rare (data not
shown). Therefore, in CRLM, the percentage of CD3+
lymphocytes were decreased, CD3 + CD4+ cells trended
to decrease, and CD3 + CD8+ TIL were increased com-
pared to non-TIL from control livers.
To determine T cell activation phenotype, lymphocytes
from both control liver and metastatic liver tumor tissue
were evaluated for cell surface expression of the T cell acti-
vation markers CD69 and CD107a. CD4 +CD107a + and
CD8 +CD69+ populations were increased in CRLM com-
pared to populations in non-tumor liver tissue (7.4% ± 0.7
vs. 3.5% ± 0.8, p = 0.04 ; 50% ± 0.9 vs. 30.6% ± 0.5 p =
0.0003 , respectively) (Figure 2C). There was no difference
in CD4 +CD69+ cells between the groups and a trend to-
wards increased CD8 +CD107a + expression on TIL com-
pared to non-TIL (27.1% ± 3.6 vs. 22.9% ± 4.5, p = 0.NS ;
10.3% ± 1.2 vs. 6.9% ± 0.6, p = 0.08 , respectively, Figure 2D).
Therefore, TIL demonstrated a higher expression of T-cell
surface markers indicative of an activated phenotype.Cytokine profiles within colorectal cancer liver metastases
To gain further insight on the immune microenvironment
within colorectal cancer liver metastases, cytokine profiles
were evaluated in both control liver and CRLM. Total pro-
tein was extracted from normal liver parenchyma and
CRLM and normalized. Liver tumor tissue contained in-
creased levels of the T-helper 1 (Th1) cytokines IFN gamma
(p = 0.000008), IL-12 (p = 0.00002), IL-1b (p = 0.00001), and
IL-8 (p = 0.0000002) compared to control liver tissue
(Figure 3). There was no difference in T-helper 2 (Th2) cy-
tokines (IL-4, IL-5, and IL-10) between the groups. The
cytokine expression profile in the tumor microenvironment
was indicative of Th1 cell-mediated immunity.
LIGHT expression in colorectal cancer liver metastases
We have previously identified intratumoral LIGHT gene
expression as associated with survival after resection of
CRLM, therefore, we sought to quantify and identify
sources of LIGHT expression in healthy liver and in
CRLM. When controlled for total lymphocyte cell popula-
tions, CD3 + T cells from CRLM had decreased LIGHT ex-
pression compared to CD3+ cells from control liver tissue
(10.1% ± 4.0 vs. 21.1% ± 2.7, p = 0.017) (Figure 4). Similarly,
expression of LIGHT was decreased in CD4+ T-cells from
CRLM (16.5% ± 2.4 vs. 29% ± 1.7 vs., p = 0.007). LIGHT
was expressed at very low levels by both intrahepatic and
intratumoral CD8 + T-cells. In addition, LIGHT expression
was decreased in both CD3+ (41% vs. 31%) and CD4+
(41% vs. 32%) T-cells and minimally expressed in CD8+
cells (<1%) from peripheral blood mononuclear cells in



































































































Figure 2 Phenotype and function of T-cell subsets in colorectal liver metastases: Intrahepatic lymphocytes and tumor infiltrating lymphocytes
were isolated. Lymphocyte populations were decreased in the metastatic deposits compared to lymphocytes isolated from livers harvested from control
animals, though the percentage of CD3 + CD8+ T-cells was increased, and overall reflected an activated phenotype. A. CD3+ cells as a percentage of total
lymphocytes in metastatic tumor tissue was lower compared to the number of CD3+ T cells in corresponding control liver (mean ± SEM : 37.5%± 1.4 vs.
51.6 %± 1.5, p = 0.00001, n = 11 per group). CD4+ cells as a percentage of total lymphocytes in metastatic tumor tissue was lower compared to the
number of CD4+ T cells in corresponding control liver (8.7%± 1.9 vs. 18.8%± 2.5, p = 0.00002, n = 11 per group). B. CD3 + CD4+ populations trended to be
less in tumor deposits than normal liver (22.4%± 5.6 vs. 34.5%± 5.4, p = 0.14, n = 11 per group). CD3 + CD8+ cells were significantly increased in the CRLM
(38.6%± 3.2 vs. 20.2%± 1.7, p = 0.00006, n = 11 per group). C,D. CD4 + CD107a + and CD8 + CD69+ populations were increased in CRLM (7.4%± 0.7 vs.
3.5%± 0.8, p = 0.04 ; 50%± 0.9 vs. 30.6%± 0.5 p = 0.0003, respectively, n = 3 per group) . There was no difference in CD4 + CD69+ cells between the
groups and a trend towards increased CD8 + CD107a + expression on TIL compared to non-TIL (27.1%± 3.6 vs. 22.9%± 4.5, p = NS ; 10.3%± 1.2 vs. 6.9%±
0.6, p = 0.08 , respectively, n = 3 per group). CRLM= colorectal liver cancer metastases. TIL = tumor infiltrating lymphocytes.
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expression and lymphocytes in CRLM
To define the areas in the tumor responsible for both
T-cell infiltrate and LIGHT expression, immunofluor-






































Figure 3 Cytokines in the tumor microenvironment of colorectal canc
immune milieu in metastatic tumors (n = 7) compared to control liverCD3+ (14 ± 2.08 vs. 2.33 ± .67, p = .00006), CD4+ (8 ±
1.86 vs. 1.67 ± 0.33, p = .0009) and CD8+ (7 ± 2.33 vs.
2.0 ± 0.58, p = .029) lymphocytes were decreased in CRLM
compared to lymphocytes from corresponding and equal





er liver metastases: Th1 cytokine responses dominated the
(n = 8).
Figure 4 LIGHT expression is decreased in CD3+ and CD4+ intratumoral lymphocytes. A. Representative flow cytometry histogram of LIGHT
expression in different T cell subsets. B. Summary of flow cytometry analysis of T cells from tumor tissues reveals decreased LIGHT expression on
CD3+ and CD4+ lymphocytes. Twenty-one percent of control liver CD3+ cells were LIGHT + compared to 10.1% in CRLM (p = 0.017, n=7 per group).
Similarly, 29% of control liver CD4+ cells were LIGHT + compared to 16.5% in CRLM (p = 0.007, n=3 per group).
Qin et al. Journal of Translational Medicine 2013, 11:70 Page 6 of 10
http://www.translational-medicine.com/content/11/1/70with FACS analysis, CRLM contained a decreased num-
ber of LIGHT expressing lymphocytes compared to
non-tumor liver tissue. Total CD3 + LIGHT+ cells were
decreased in tumor bearing liver compared to control
(0.33 ± 0.33 vs. 9 ± 2.65, p = .00006) (Figure 5). Similarly,
CD4 + LIGHT+ (0. 33 ± 0.33 vs. 5.33 ± .88, p = .0009) and
CD8 + LIGHT+ (1.33 ± .67 vs. 3.67 ± 1.33, p = .029) cells
were decreased in tumor bearing liver compared to con-
trol (Figure 5). LIGHT expression was only present on
lymphocytes and no LIGHT expression was identified
on the CRLM or in the tumor stroma.In regard to the architectural location of the T-cells in
the tumor microenvironment, the number of LIGHT-
expressing CD3+ (6.33 ± 2.40 vs. 0.33 ± .33, p = .000056),
CD4+ (5.33 ± 1.20 vs. 0.33 ± .33, p = .0009), and CD8+
(5.67 ± 2.40 vs. 1.67 ± 0.33, p = .029) lymphocytes were
significantly higher in the peritumor region compared to
the intratumor region (Figure 5).
Discussion
The presence of immune cells within primary colorec-
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Figure 5 Concurrent immunofluorescence staining of lymphocytes and LIGHT: Representative images of CD4+ staining (A,D red),
LIGHT positive staining (B,E green) and co-expression (C,F yellow). DAPI was utilized as a nuclear counterstain (blue). Upper panels at low
power identify an area of CD4+ TIL infiltration in a resected colorectal liver metastasis (200x). Lower panels demonstrate a single high power field
in a peritumoral specimen (400x). Intratumoral CD3+ (14 ± 2.08 vs. 2.33 ± .67, p = .00006), CD4+ (8 ± 1.86 vs. 1.67 ± 0.33, p = .0009) and CD8+ (7 ± 2.33 vs.
2.0 ± 0.58, p = .029) lymphocytes were decreased in CRLM compared to lymphocytes from corresponding and equal areas of healthy control liver. Total
CD3 + LIGHT + (0.33 ± 0.33 vs. 9 ± 2.65, p = .00006), CD4 + LIGHT + (0. 33 ± 0.33 vs. 5.33 ± .88, p = .0009) and CD8 + LIGHT + (1.33 ± .67 vs. 3.67 ± 1.33,
p = .029) cells were decreased in tumor bearing liver compared to control. LIGHT-expressing CD3+ (6.33 ± 2.40 vs. 0.33 ± .33, p = .00006), CD4+ (5.33 ±
1.20 vs. 0.33 ± .33, p = .0009), and CD8+ (5.67 ± 2.40 vs. 1.67 ± 0.33, p = .029) lymphocytes were significantly higher in the peritumor region compared to
the intratumor region (panels G-I)(n = 6).
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CD8+ TIL was associated with improved survival for
patients with colorectal cancer, with 100% three-year
survival of patients whose tumors contained a high
density of intratumoral CD8 + TIL [20]. Similar to
these observations made in primary colon tumors, the
presence of increased CD4 and CD8 T cell infiltrates
identified by immunohistochemistry in CRLM has also
been associated with improved recurrence free and
overall survival [8,9]. In another study, tumor infiltrat-
ing lymphocytes from resected human CRLM were
found to respond against tumor antigens, in most pa-
tients, and flow cytometry of the TIL identified propor-
tions of activated effector T-cells [21]. Furthermore,genetic ontology analysis of over 90 resected human
CRLM identified T-cell activation as the most signifi-
cant biologic function associated with recurrence free
survival [10]. Based on these previous studies, increased
T-cell infiltration into primary and metastatic colon
cancer tumors is associated with improved survival and
may be reflective of an anti-tumor and antigen-specific
immune response. Therefore, immunostimulatory strat-
egies that increase T cell infiltration into colorectal can-
cer liver metastases may be an ideal strategy for CRLM
immunotherapy.
However, what is not clearly understood is how the im-
mune microenvironment of CRLM differs from the rest
of the liver, including determination of the phenotype,
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lymphocytes. Furthermore, identification of the immuno-
modulatory cytokines present in the tumors, the type of
cellular immunity generated by the tumor, and identifica-
tion of potential targets that can be manipulated to in-
crease the anti-tumor response remains to be elucidated.
This gap in knowledge was investigated in order to
characterize the CRLM immune microenvironment and
identify novel immunotherapeutic strategies.
Immunotherapy has yielded successes in treating other
human malignancies utilizing a variety of active and passive
immunity strategies. Though in some cases tumor regres-
sion was obtained by adoptive transfer of TIL [22] or
tumor specific antigen vaccines [23,24], tumor responses
have also been achieved using immunostimulatory cyto-
kines and antibodies that block immunosuppressive sig-
nals, e.g. CTLA4 [25-28]. For many cancers, therapy will
likely transition toward a combination of immunotherapy
and other targeted strategies to improve outcomes [29].
To determine the optimal immunotherapeutic strategy
for CRLM, the tumor microenvironment must first be
characterized. This has proven difficult secondary to the
heterogeneity of metastatic patient tumors, the scarcity of
TIL in colorectal cancer liver metastases, and inappropriate
animal models. Though limited in that it may bypass cer-
tain biologic phenomena that occur during primary tumor
progression, we have created a reliable model that ad-
dresses these issues and mimics many aspects of the hu-
man course of disease by utilizing a well established
syngeneic murine model of CRLM [30,31].
Using this model, it was determined that, as in human
CRLM, there were low levels of TIL overall and de-
creased levels of CD3 and CD4+ T-cells compared to
non-tumor liver parenchyma. CRLM CD4+ subsets were
decreased both in total and when calculated as a percent-
age of CD3+ cells, corresponding with decreased expres-
sion of CD3+ and CD4+ cells in CRLM on microscopy of
independent tumor sections. Interestingly, numbers of
CRLM CD8+ TIL were rare and not significantly differ-
ent compared to non-tumor bearing liver populations
when calculated as a percentage of total lymphocytes.
However, when calculated as a percentage of CD3+ cells,
a more accurate reflection of the percent of CD8+ cells
(that also removed non-T-cell populations from the ana-
lysis), CD8+ cells were found to be significantly increased
in the tumors. This would indicate infiltration of cyto-
toxic T-cells into the tumor microenvironment driven by
tumor specific factors. Although it was demonstrated
that the levels of CD4+ lymphocytes were decreased
within CRLM compared to healthy liver, the CD4+ TIL
were activated (increased CD4 + CD107a) compared to
normal liver CD4+ cells, and these CD4+ TIL were per-
haps driving the increased expression and activation of
the CD8+ TIL. This is supported by cytokine analysis ofthe tumor microenvironment that reflected a Th1 cell-
mediated immune response within the tumor with in-
creased levels of IFN gamma, IL-12, IL-1, and IL-8 in the
metastatic deposits. Therefore, it appears that there is an
antigen driven, tumor specific cell-mediated immune re-
sponse in CRLM, though brisk tumor infiltration was not
present and the response was insufficient to eliminate
the tumors.
When evaluated by immunofluorescence, we found
that the majority of the CD8+ cells were found in the
peritumoral tissues. Phenotypic analysis of these TIL,
however, found them to be significantly activated over
CD8+ cells not in the tumor microenvironment or in
non-tumor bearing livers. Therefore, it is possible that
the tumor stroma and a number of other immunoediting
mechanisms employed by the tumor limit the ability of
CD8+ cells to infiltrate into the tumor nests [20,32].
Therefore, mechanisms that either increase TIL numbers
and their activation status, or allow greater intratumoral
infiltration may be a specific viable therapeutic strategy.
LIGHT is an immunostimulatory cytokine that has
been shown to increase the number of TIL and their acti-
vation status, and to induce tumor regression via
upregulation of the antitumor immune response [13].
Though this has not been demonstrated in CRLM, our
gene ontology analysis of resected CRLM identified an
association between increased LIGHT expression and
survival [10]. Therefore, we were interested in character-
izing LIGHT expression in the tumor microenvironment
as a potential therapeutic target. Although FACS analysis
of cell surface markers demonstrated that the TIL were
significantly activated compared to intrahepatic lympho-
cytes, the TIL expressed significantly less LIGHT. It is
important to note that while there was a pattern of in-
creased LIGHT + staining in control liver tissue com-
pared to intratumoral tissue, the same decrease was not
present when comparing control liver tissue to peritumor
liver tissue (liver tissue immediately adjacent to the me-
tastases). Although the number of total T-cells was lower
in peritumor liver tissue compared to control liver, the
levels of LIGHT + T cells were similar, if not comparable.
Therefore, there appears to be a barrier to LIGHT ex-
pression within intratumoral TIL and this may be sup-
pressing a tumor specific immune response or may
reflect a tumor immune-escape mechanism [33,34].
In summary, characterization of the tumor microenvir-
onment of CRLM revealed that although a limited num-
ber of activated T-cells are infiltrating the tumor and
initiating an immune response, the number of LIGHT +
T cells infiltrating the tumor are very low. Considering
LIGHT has previously been shown to cause proliferation
and activation of T cells, it is possible that an increase in
LIGHT + T cells within the tumor could amplify the
existing immune response.
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model of disease rather than human tissues. However,
the heterogeneity of patient factors and variable growth
and tumor architecture of patient-derived tumors can
often limit the analysis, and this syngeneic immunocom-
petent model allows consistent and reproducible tumors
with less heterogeneity. Reproducibility of the results in
different syngeneic cell lines on alternate murine back-
grounds is needed. Furthermore, use of sham –operated
murine liver tissue to compare to tumor bearing liver
limits analysis to intrahepatic lymphocytes versus TIL.
This was felt to be a more appropriate comparison than
to use apparently uninvolved or healthy appearing liver
from the experimental mouse liver, as micrometastatic
disease may have been present. Ideally, TIL from CRLM
would be compared to TIL from benign lesions or to
CRLM treated with immunomodulatory agents. It is crit-
ical, however, to define the tumor microenvironment at
baseline compared to normal liver tissue, in order to
identify targets for future studies. What is evident from
recent data and our observations in the fixed tissues was
that critical and unique immunological interactions may
be occurring in the peritumoral milieu and stroma. For
this reason, we critically evaluated the peritumoral area
on fixed tissue slides since the domain could be identified
and defined with microscopy (Figure 5). It was not pos-
sible to accurately define or isolate sufficient numbers of
lymphocytes from the small rims of peritumoral tissue
around very small murine liver metastases, from a tech-
nical perspective, therefore, FACS analysis was not
performed separately on peritumoral tissues. In addition,
it is possible that the size of the metastases influenced
the amount of TIL in the lesions. There was variation
in the size of the lesions within the same liver, as one
would also expect in the human course, however, the
variations were relatively similar between animals. TIL
from the same animal were pooled and compared to
TIL from control animals, therefore, this should have
decreased the bias of the size of any individual meta-
static lesion. Furthermore, it would also have been in-
teresting to analyze additional T-cell subsets, however,
phenotypic and functional determination by flow cy-
tometry is limited in scope by the number of TIL that
are in the tumors. We did further evaluate CD3 +
CD4-CD8- T-cells utilizing the murine pan-NK cell
marker CD49B and speculate that many of the uncom-
mon T-cells are natural killer and γδT cells, acknow-
ledging that the liver is a reservoir for double negative
T-cells [35]. Further analysis of LIGHT levels in these
cells and in γδT cells are planned. Despite these limi-
tations, the findings of this study lay the foundation for
evaluation of future immunotherapies and validation
studies with the goal of inciting clinical regressions of
established CRLM.Conclusions
The success of immunotherapy in other diseases, and
the critical finding that colorectal cancer patients with
increased TIL live longer, has identified immunotherapy
as a potential optimal strategy for patients with CRLM.
Our current gap in knowledge is a lack of understanding
of the immune microenvironment of CRLM, and in
identifying potential immunostimulatory interventions.
We have herein characterized the phenotype and
function of TIL in the tumor microenvironment using
an immunocompetent syngeneic animal model of
CRLM, and have defined the expression of LIGHT, a
potential immunotherapeutic agent for this disease.
Based on the cytokine milieu, there appears to be Th1
cell-mediated immunity within CRLM that is supporting
a CD8+ cytotoxic T-lymphocyte based tumor specific im-
mune response. The number of CD3 + CD4+ TIL is lim-
ited, however the percent of CD3 + CD8+ TIL is
increased, and these cells have an activated phenotype.
Importantly, the majority of CD8+ cells in the tumor
microenvironment were peritumoral, and LIGHT was
barely detectable on most CD8+ TIL, which supports a
mechanism of immunosuppression on the TIL that are
migrating to and infiltrating into the metastatic tumors.
Techniques to decrease suppressive influences or aug-
ment the cytotoxic T-cell response are needed and may
be possible through mechanisms that can increase
intratumoral LIGHT + TIL. Future studies are focused
on evaluating changes in the tumor microenvironment
through increased activation and stimulation of TIL, in-
cluding with LIGHT.
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